Glenmark gets US regulatory nod for anti-hypertension tablets
Press Trust of India / Mumbai Jun 01, 2009, 13:35 IST
Glenmark Pharmaceuticals today said it has received the final approval from the US drug regulator for the marketing of its anti- hypertension tablets.
Glenmark Generics, a subsidiary firm of the company, has received the final approval from the US Food and Drug Administration (US FDA) for its hydralazine hydrochloride tablets, used for the treatment of hypertension, Glenmark Pharmaceuticals said in a filing to the Bombay Stock Exchange.